-
MicroPort CardioFlow’s Heart Valve Balloon Dilatation Catheter Alwide Plus Gains Mexican Approval
•
MicroPort Scientific Corp., a leading Chinese medical device company (HKG: 0853), through its spin-off MicroPort CardioFlow Medtech Co., Ltd (HKG: 2160), has announced that it has received market approval for its heart valve balloon dilatation catheter, Alwide Plus, from the Comisión Federal para la Protección contra Riesgos Sanitarios (COFEPRIS) in…
-
MicroPort CardioFlow Medtech’s AltaValve Receives FDA Breakthrough Designation for Mitral Regurgitation Treatment
•
MicroPort Scientific Corp (HKG: 0853), a leading medical device company based in China, has announced that its spin-off, MicroPort CardioFlow Medtech Co., Ltd (HKG: 2160), has received Breakthrough Devices status from the US Food and Drug Administration (FDA) for its AltaValve transcatheter mitral valve replacement device. This product, co-developed with…
-
MicroPort CardioFlow Medtech’s VitaFlow Liberty Receives CE Mark for European Expansion
•
China-based MicroPort Scientific Corp (HKG: 0853), a leading medical device company, announced that its spin-off, MicroPort CardioFlow Medtech Co., Ltd (HKG: 2160), has secured the CE mark for its VitaFlow Liberty transcatheter aortic valve and its recyclable delivery system. This regulatory approval paves the way for the product’s market entry…
-
MicroPort CardioFlow Medtech Reports 33.9% YOY Revenue Growth in 2023 Financials
•
MicroPort CardioFlow Medtech Co., Ltd (HKG: 2160), a spin-off from China-based MicroPort Scientific Corp (HKG: 0853), has announced its financial report for 2023. The company reported a 33.9% year-on-year (YOY) increase in revenue, reaching RMB 336 million (USD 46.5 million), with gross profits surging 41.8% to RMB 223 million (USD…
-
MicroPort CardioFlow Forecasts 31%-36% YOY Sales Growth for 2023 Driven by TAVI Product Expansion
•
MicroPort CardioFlow Medtech Co., Ltd (HKG: 2160), a spin-off from China-based MicroPort Scientific Corp (HKG: 0853), has announced a forecast for its 2023 financial performance along with key business updates. The company anticipates generating sales within the range of RMB 330 million to RMB 340 million for the year, reflecting…
-
MicroPort CardioFlow Medtech’s AnchorMan System Receives NMPA Approval as First Semi-Closed LAA Occluder in China
•
MicroPort Scientific Corp (HKG: 0853), a leading medical device company based in China, has announced that its spin-off, MicroPort CardioFlow Medtech Co., Ltd (HKG: 2160), has received marketing approval from the National Medical Products Administration (NMPA) for La Ronda’s AnchorMan left atrial appendage occluder system. This marks the first semi-closed…
-
MicroPort CardioFlow Medtech to Acquire Controlling Stake in La Ronda for USD 20 Million
•
MicroPort CardioFlow Medtech Co., Ltd (HKG: 2160), a spin-off of China-based MicroPort Scientific Corp (HKG: 0853), has announced that a conditional agreement has been reached to acquire a 51% stake in fellow Chinese firm La Ronda for a cash consideration of RMB 141 million (USD 20 million). La Ronda, based…
-
MicroPort CardioFlow Medtech Completes Clinical Implantations of Second-Generation TAVI Device
•
MicroPort CardioFlow Medtech Co., Ltd (HKG: 2160), a spin-off of China-based MicroPort Scientific Corp (HKG: 0853), has announced the successful completion of seven clinical implantations of its second-generation transcatheter aortic valve implantation (TAVI) product, VitaFlow Liberty. The surgeries were performed in Denmark and Ireland, with all patients recovering well post-operation.…
-
MicroPort CardioFlow Medtech’s Third-Generation TAVI Product Achieves Initial Clinical Success
•
MicroPort CardioFlow Medtech Co., Ltd (HKG: 2160), a spin-off from China-based MicroPort Scientific Corp (HKG: 0853), has announced the successful completion of the first two clinical applications of its third-generation transcatheter aortic valve implantation (TAVI) product. This advanced medical device features a recyclable and controllable bend delivery system, which was…
